Farkas Andrea csodálatos és egyben ijesztő érzésről mesél új könyvében blikk.hu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from blikk.hu Daily Mail and Mail on Sunday newspapers.
Emyria to focus on initiating and completing pivotal clinical trials for EMD-003 program and advancing EMD-004 program
EMD-003 is being developed to reduce anxiety, depression and stress symptoms while the company is also advancing EMD-004 targeting irritable bowel syndrome. The company secured access to a unique CBD dose product via a partnership with Cann Group
Emyria Ltd (ASX:EMD) will continue its focus on initiating and completing pivotal clinical trials for the EMD-003 program, seeking to register a cannabinoid-based medicine with a unique capsule dose form to reduce symptoms of anxiety, depression and stress.
The data-backed drug development company is also advancing the EMD-004 program targeting irritable bowel syndrome and scoping pipeline expansion therapeutically (with psychedelic-assisted therapy) and geographically with the US Food and Drug Administration (FDA) pathways.